Amarin : Investor Conference Presentation

Published: 2025-06-24 07:33:05 ET AMRN

Published on 06/24/2025 at 07:33

UNDERPINNED BY VASCEPA/VAZKEPA GLOBAL GROWTH OPPORTUNITY

Large global burden of disease and need for CV risk reduction

60M patients with CVD in Europe

Powerful REDUCE-IT data; Proven efficacy and safety

Broad global KOL and scientific guideline support; 50+ endorsements from

leading medical societies

Unique and complementary to current therapies

CVRR Indication regulatory approvals in

49 global markets

RIGHT-SIZING ORGANIZATION TO DRIVE EFFICIENT REVENUE GLOBALLY & ACCELERATE POSITIVE CASH FLOW

Global restructuring expected to generate ~$70M in cost savings over next 12 months

New strategic pathway to further maximize VAZKEPA in Europe

RECORDATI EXCLUSIVE LICENSE & SUPPLY AGREEMENT TO COMMERCIALIZE VAZKEPA IN EUROPE

IN EUROPE AND INCREASE SHAREHOLDER VALUE

EXPLORING OPTIONS TO MAXIMIZE SHAREHOLDER VALUE

Continue to explore potential additional strategic opportunities to create shareholder value

Significant steps being taken to accelerate path to positive cash flow and strengthen strategic position for the future

3

CORPORATE ACTIONS TO EXPAND VAZKEPA PATIENT USE

RECORDATI AGREEMENT

TRANSACTION IMMEDIATELY STRENGTHENS FINANCIAL POSITION IN NEAR- AND LONG-TERM

LEVERAGING RECORDATI'S PROVEN EXPERTISE TO ACCELERATE DEPTH AND REACH OF VAZKEPA FOR PATIENTS

Long and extensive cardiovascular disease heritage

upfront cash

milestone payments contingent upon Recordati achieving predefined commercial net sales levels

for supply of product to Recordati

4

MAXIMIZING VAZKEPA OPPORTUNITY IN EUROPE WITH

VAZKEPA IN EUROPE: RECENT PROGRESS & LONG IP RUNWAY CREATE OPPORTUNITY FOR SIGNIFICANT GROWTH BY RECORDATI

Exclusive long-term license and supply agreement to commercialize VAZKEPA across 59 countries, focused in Europe

Partner with strong cardiovascular expertise & established commercial and medical presence across all European markets can amplify progress & accelerate uptake

RECENT PROGRESS PROVIDES FAVORABLE MARKET DYNAMICS TO ACCELERATE GROWTH

Pricing & Reimbursement secured and access opened to over half of eligible patient population in Western Europe

Commercially available in 10 European and Central and Eastern Europe markets

Unlocked regional access accounting for 91% of eligible patient population in Italy shortly after national reimbursement; country now ready for full commercial launch

Strong medical advocacy and support across Europe; inclusion of VAZKEPA in multiple European and national guidelines & protocols

Revised potential strategies for resubmission in France and Germany identified

VAZKEPA PRICING & REIMBURSEMENT / COMMERCIALIZATION PROGRESS

Reimbursed & launched

Positive HTA / final price negotiations

Resubmission strategy identified

Smaller / mid-sized markets - pot. future reimbursement 5

Disclaimer

Amarin Corporation plc published this content on June 24, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 24, 2025 at 11:32 UTC.